Results 51 to 60 of about 677,841 (292)

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

A unified model for Duchenne muscular dystrophy gene involvement in cancer: context‐dependent tumour suppression and oncogenicity

FEBS Open Bio, EarlyView.
We propose a context‐dependent model where the Duchenne muscular dystrophy (DMD) gene acts as a tumour suppressor in aggressive tumours and as an oncogene in less aggressive ones. We propose this model as a unified framework to explain the opposing survival associations with DMD expression and to guide experimental exploration of the dual role of DMD ...
Lee Machado, Leanne Jones, Sonika Divakar, Michael Naidoo, Karen Anthony   +4 more
wiley   +1 more source

Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry [PDF]

, 2012
Atsushi Nashimoto, Kohei Akazawa, Yoh Isobe, Isao Miyashiro, Hitoshi Katai, Yasuhiro Kodera, Shunichi Tsujitani, Yasuyuki Seto, Hiroshi Furukawa, Ichiro Oda, Hiroyuki Ono, Satoshi Tanabe, Michio Kaminishi   +12 more
openalex   +1 more source

Rethinking plastic waste: innovations in enzymatic breakdown of oil‐based polyesters and bioplastics

FEBS Open Bio, EarlyView.
Plastic pollution remains a critical environmental challenge, and current mechanical and chemical recycling methods are insufficient to achieve a fully circular economy. This review highlights recent breakthroughs in the enzymatic depolymerization of both oil‐derived polyesters and bioplastics, including high‐throughput protein engineering, de novo ...
Elena Rosini, Nicolò Antonelli, Gianluca Molla   +2 more
wiley   +1 more source

OPTN/SRTR 2015 Annual Data Report: Pancreas [PDF]

, 2017
Raja Kandaswamy, Peter G. Stock, S.K. Gustafson, M.A. Skeans, Michael Curry, Matthew Prentice, Ajay K. Israni, Jon J. Snyder, B.L. Kasiske   +8 more
openalex   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

NSW Annual Adverse Events Following Immunisation Report, 2009 [PDF]

, 2010
Deepika Mahajan, Sue Campbell‐Lloyd, Ilnaz Roomiani, Robert Menzies   +3 more
openalex   +1 more source

Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays

FEBS Open Bio, EarlyView.
We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop   +3 more
wiley   +1 more source

Annual Report 2024

AIMS Allergy and Immunology
This editorial note is dedicated to the 2024 Journal report of AIMS Allergy and Immunology, which was run by AIMS Press. After a brief summary about the annual development in 2024, future developments of the journal in 2025 are proposed.
Marcella Reale, Xu Guo
doaj   +3 more sources

Comment on Giacosa et al. Characterization of Annual Air Emissions Reported by Pulp and Paper Mills in Atlantic Canada. Pollutants 2022, 2, 135–155 [PDF]

, 2022
Alicia Berthiaume, Anne Monette, Jody Rosenberger, Bernard Lupien   +3 more
openalex   +1 more source